Skip to main content
SpringerLink
Log in

Predictive Factors Analysis for Malignant Peritoneal Mesothelioma

  • Original Article
  • Published:
Journal of Gastrointestinal Surgery Aims and scope

Abstract

Background

Malignant peritoneal mesothelioma (MPM) is an uncommon disease with a dismal prognosis and unclear natural history. The present study aims to assess potential prognostic factors and management of MPM.

Methods

Clinical records of 39 patients with MPM between December 2003 and April 2014 were retrospectively reviewed. Overall survival was identified with Kaplan-Meier curves and Cox regression analysis.

Results

Mean age of 39 patients was 55.0 years; asbestos exposure was recorded in two patients. Main presentations were abdominal distension, abdominal pain, and weight loss. Thrombocytosis, low serum albumin level, and anemia were principal laboratory abnormalities. Ascites, peritoneal cavity mass, and peritoneum thickening were the main signs on CT scans. Cytoreductive surgery (CRS) plus adjuvant therapies were performed in 22 patients, single chemotherapy in 13, and best supportive care in 4. Median survival time was 10.0 months after pathological diagnosis, with a 6-, 12-, 18-, and 24-month survival rate of 84.4, 31.6, 18.5, and 15.8 %, respectively. Significant prognostic factors were age, performance status (PS), abdominal pain, serum albumin level, thrombocytosis, and treatment strategy on univariate analysis, while only age, abdominal pain, and treatment strategy hold statistical significance on multivariate analysis.

Conclusions

Age ≤65 years, abdominal pain, and CRS plus adjuvant therapy are independent positive prognostic factors of MPM.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Moore AJ, Parker RJ, Wiggins J. Malignant mesothelioma. Orphanet J Rare Dis 2008;3:34.

    Article  PubMed Central  PubMed  Google Scholar 

  2. Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med 2005;353:1591–1603.

    Article  CAS  PubMed  Google Scholar 

  3. Roe OD, Creaney J, Lundgren S, Larsson E, Sandeck H, Boffetta P, Nilsen TI, Robinson B, Kjaerheim K. Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case–control study. Lung Cancer 2008;61:235–243.

    Article  PubMed  Google Scholar 

  4. Garcia-Carbonero R, Paz-Ares L. Systemic chemotherapy in the management of malignant peritoneal mesothelioma. EJSO 2006;32:676–681.

    Article  CAS  PubMed  Google Scholar 

  5. Munkholm-Larsen S, Cao CQ, Yan TD. Malignant peritoneal mesothelioma. World J Gastrointest Surg 2009;1:38–48.

    Article  PubMed Central  PubMed  Google Scholar 

  6. Sebbag G, Yan H, Shmookler BM, Chang D, Sugarbaker PH. Results of treatment of 33 patients with peritoneal mesothelioma. Br J Surg 2000;87:1587–1593.

    Article  CAS  PubMed  Google Scholar 

  7. Wagner JC, Sleegs CA, Marchand P. Diffuse pleural mesothelioma. Br J Ind Med 1960;17:260–271.

    CAS  PubMed Central  PubMed  Google Scholar 

  8. Cunha P, Luz Z, Seves I, Sousa C, Skiappa, Ribeiro L, Marques C, Oliveira M. Malignant peritoneal mesothelioma-diagnostic and therapeutic difficulties. Acta Med Port 2002;15:383–386.

    CAS  PubMed  Google Scholar 

  9. Sharma H, Bell I, Schofield J, Bird G. Primary peritoneal mesothelioma: case series and literature review. Clin Res Hepatol Gastroenterol 2011;35:55–59.

    Article  CAS  PubMed  Google Scholar 

  10. Piazza D, Caruso F, Scaringi S, Ferrara M, Latteri F, Dell’Erba D. Primary diffuse malignant peritoneal mesothelioma: case report and update of therapy. J Surg Oncol 2000;75:55–58.

    Article  CAS  PubMed  Google Scholar 

  11. Tan GH, Cheung M, Chanyaputhipong J, Soo KC, Teo MC. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma. Ann Acad Med Singapore 2013;42:291–296.

    PubMed  Google Scholar 

  12. Mirarabshahii P, Pillai K, Chua TC, Pourgholami MH, Morris DL. Diffuse malignant peritoneal mesothelioma-an update on treatment. Cancer Treat Rev 2012;38:605–612.

    Article  PubMed  Google Scholar 

  13. Magge D, Zenati MS, Austin F, Mavanur A, Sathaiah M, Ramalingam L, Jones H, Zureikat AH, Holtzman M, Ahrendt S, Pingpank J, Zeh HJ, Bartlett DL, Choudry HA. Malignant peritoneal mesothelioma: prognostic factors and oncologic outcome analysis. Ann Surg Oncol 2014;21:1159–1165.

    Article  PubMed  Google Scholar 

  14. Baratti D, Kusamura S, Cabras AD, Bertulli R, Hutanu I, Deraco M. Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC). Eur J Cancer 2013;49:3140–3148.

    Article  PubMed  Google Scholar 

  15. Acherman YI, Welch LS, Bromley CM, Sugarbaker PH. Clinical presentation of peritoneal mesothelioma. Tumori 2003;89:269–273.

    PubMed  Google Scholar 

  16. Damhuis RA, Schroten C, Burgers JA. Population-based survival for malignant mesothelioma after introduction of novel chemotherapy. Eur Respir J 2012;40:185–189.

    Article  PubMed  Google Scholar 

  17. Cao C, Yan TD, Deraco M, Elias D, Glehen O, Levine EA, Moran BJ, Morris DL, Chua TC, Piso P, Sugarbaker PH; Peritoneal Surface Malignancy Group. Importance of gender in diffuse malignant peritoneal mesothelioma. Ann Oncol 2012;23:1494–1498.

    Article  CAS  PubMed  Google Scholar 

  18. Park JY, Kim KW, Kwon HJ, Park MS, Kwon GY, Jun SY, Yu ES. Peritoneal mesotheliomas: clinicopathologic features, CT findings, and differential diagnosis. AJR Am J Roentgenol 2008;191:814–825.

    Article  PubMed  Google Scholar 

  19. Manzini Vde P, Recchia L, Cafferata M, Porta C, Siena S, Giannetta L, Morelli F, Oniga F, Bearz A, Torri V, Cinquini M. Malignant peritoneal mesothelioma: a multicenter study on 81 cases. Ann Oncol 2010;21:348–353.

    Article  PubMed  Google Scholar 

  20. Iversen LH, Rasmussen PC, Laurberg S. Value of laparoscopy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis. Br J Surg 2013;100:285–292.

    Article  CAS  PubMed  Google Scholar 

  21. Wang J, Gao L, Tang S, Li T, Lei Y, Xie H, Liang J, Chen B, Wang X, Fan D. A retrospective analysis on the diagnostic value of ultrasound-guided percutaneous biopsy for peritoneal lesions. World J Surg Oncol 2013;11:251.

    Article  PubMed Central  PubMed  Google Scholar 

  22. Krasuski P, Poniecka A, Gal E. The diagnostic challenge of peritoneal mesothelioma. Arch Gynecol Obstet 2002;266:130–132.

    Article  CAS  PubMed  Google Scholar 

  23. Chen LY, Huang LX, Wang J, Qian Y, Fang LZ. Malignant peritoneal mesothelioma presenting with persistent high fever. J Zhejiang Univ Sci B 2011;12:381–384.

    Article  PubMed Central  PubMed  Google Scholar 

  24. Alexander HR Jr. Surgical treatment of malignant peritoneal mesothelioma: past, present, and future. Ann Surg Oncol 2010;17:21–22.

    Article  PubMed Central  PubMed  Google Scholar 

  25. Turner K, Varghese S, Alexander HR Jr. Current concepts in the evaluation and treatment of patients with diffuse malignant peritoneal mesothelioma. J Natl Compr Canc Netw 2012;10:49–57.

    CAS  PubMed  Google Scholar 

  26. Yan TD, Yoo D, Sugarbaker PH. Significance of lymph node metastasis in patients with diffuse malignant peritoneal mesothelioma. Eur J Surg Oncol 2006;32:948–953.

    Article  CAS  PubMed  Google Scholar 

  27. Yan TD, Deraco M, Baratti D, Kusamura S, Elias D, Glehen O, Gilly FN, Levine EA, Shen P, Mohamed F, Moran BJ, Morris DL, Chua TC, Piso P, Sugarbaker PH. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol 2009;27:6237–6242.

    Article  PubMed  Google Scholar 

  28. O’Brien ME, Watkins D, Ryan C, Priest K, Corbishley C, Norton A, Ashley S, Rowell N, Sayer R. A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial. Ann Oncol 2006;17:270–275.

    Article  PubMed  Google Scholar 

  29. Simon GR, Verschraegen CF, Jänne PA, Langer CJ, Dowlati A, Gadgeel SM, Kelly K, Kalemkerian GP, Traynor AM, Peng G, Gill J, Obasaju CK, Kindler HL. Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial. J Clin Oncol 2008;26:3567–3572.

    Article  CAS  PubMed  Google Scholar 

  30. Cao SB, Jin S, Cao JY, Shen J, Zhang JW, Yu Y. Colonic invasion induced by malignant peritoneal mesothelioma. Int J Colorectal Dis 2014;29:891–892.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by Wujieping Foundation (No. 320.6750.12204), Young People Research Fund for the grant National Natural Scientific Foundation of China (No. 81201828), Young People Foundation of Heilongjiang Provincial of China (No. QC2012C013), National Natural Scientific Foundation of China (No. 81101758), Health Department of Heilongjiang Provincial of China (No: 2011-124) and Harbin Medical University Cancer Hospital major project Foundation (No: JJZ-2010-01).

Conflict of Interest

None.

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Harbin Medical University Cancer Hospital, No. 150 Haping Road, Harbin, 150081, China

    Shi Jin, Shoubo Cao, Jingyan Cao, Jing Shen, Jing Hu, Dehai Che, Jiawen Zhang & Yan Yu

Authors
  1. Shi Jin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shoubo Cao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jingyan Cao
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jing Shen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jing Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Dehai Che
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jiawen Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yan Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yan Yu.

Additional information

Shi Jin and Shoubo Cao contributed equally to this work and should be considered co-first authors.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jin, S., Cao, S., Cao, J. et al. Predictive Factors Analysis for Malignant Peritoneal Mesothelioma. J Gastrointest Surg 19, 319–326 (2015). https://doi.org/10.1007/s11605-014-2664-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11605-014-2664-4

Keywords

Search

Navigation